These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 10089183)

  • 1. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
    Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
    N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
    N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
    N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
    Farraj RS
    Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
    N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
    N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.
    Schulman S; Rhedin AS; Lindmarker P; Carlsson A; Lärfars G; Nicol P; Loogna E; Svensson E; Ljungberg B; Walter H
    N Engl J Med; 1995 Jun; 332(25):1661-5. PubMed ID: 7760866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
    Crowther MA; Ginsberg JS; Julian J; Denburg J; Hirsh J; Douketis J; Laskin C; Fortin P; Anderson D; Kearon C; Clarke A; Geerts W; Forgie M; Green D; Costantini L; Yacura W; Wilson S; Gent M; Kovacs MJ
    N Engl J Med; 2003 Sep; 349(12):1133-8. PubMed ID: 13679527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended prophylaxis of venous thromboembolism with idraparinux.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
    N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
    Wells PS; Forgie MA; Simms M; Greene A; Touchie D; Lewis G; Anderson J; Rodger MA
    Arch Intern Med; 2003 Apr; 163(8):917-20. PubMed ID: 12719200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.
    Schulman S; Lindmarker P
    N Engl J Med; 2000 Jun; 342(26):1953-8. PubMed ID: 10874063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
    Aujesky D; Smith KJ; Roberts MS
    Am J Med; 2005 Jun; 118(6):625-35. PubMed ID: 15922694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
    Kearon C; Ginsberg JS; Kovacs MJ; Anderson DR; Wells P; Julian JA; MacKinnon B; Weitz JI; Crowther MA; Dolan S; Turpie AG; Geerts W; Solymoss S; van Nguyen P; Demers C; Kahn SR; Kassis J; Rodger M; Hambleton J; Gent M;
    N Engl J Med; 2003 Aug; 349(7):631-9. PubMed ID: 12917299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The study of Chinese optimal anticoagulant range of warfarin for venous thromboembolism].
    Yang P; Wu QH; Luo XY; Kou L; Chen Z; Zhang YY; Zhou H
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(25):1762-5. PubMed ID: 19862981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.
    Agnelli G; Piovella F; Buoncristiani P; Severi P; Pini M; D'Angelo A; Beltrametti C; Damiani M; Andrioli GC; Pugliese R; Iorio A; Brambilla G
    N Engl J Med; 1998 Jul; 339(2):80-5. PubMed ID: 9654538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement.
    Turpie AG; Gent M; Laupacis A; Latour Y; Gunstensen J; Basile F; Klimek M; Hirsh J
    N Engl J Med; 1993 Aug; 329(8):524-9. PubMed ID: 8336751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
    Couturaud F; Sanchez O; Pernod G; Mismetti P; Jego P; Duhamel E; Provost K; dit Sollier CB; Presles E; Castellant P; Parent F; Salaun PY; Bressollette L; Nonent M; Lorillon P; Girard P; Lacut K; Guégan M; Bosson JL; Laporte S; Leroyer C; Décousus H; Meyer G; Mottier D;
    JAMA; 2015 Jul; 314(1):31-40. PubMed ID: 26151264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
    Bergqvist D; Agnelli G; Cohen AT; Eldor A; Nilsson PE; Le Moigne-Amrani A; Dietrich-Neto F;
    N Engl J Med; 2002 Mar; 346(13):975-80. PubMed ID: 11919306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.